Adapt Pharma of Radnor is trying to make Narcan, a nasal-spray antidote to an opioid overdose, as widely available as a flu shot, writes Erin Arvedlund for The Philadelphia Inquirer.
Every day, an estimated 115 people die from opioid overdoses. About half of that number dies from prescription drugs. The other half dies from illegal use.
“We’re trying to make sure first responders, hospitals, universities all have access to our Narcan nasal spray,” Adapt Pharma CEO Seamus Mulligan said in an interview from Dublin, his native city and site of the company’s worldwide headquarters.
Mulligan splits his time between Ireland and Radnor, where Adapt Pharma has its U.S. headquarters. Adapt employs roughly 50 people, 30 in the U.S. and the remainder in Dublin.
Like many drugs, cost has been a sore point.
Narcan is available without a prescription at participating pharmacies at a retail cost of $125 for two doses. In response to the opioid epidemic, Adapt Pharma prices Narcan 40 percent lower for nonprofits, first responders, schools, and government agencies, which pay $75 for two doses.
Read more about Narcan in The Philadelphia Inquirer by clicking here.